You are here: Home: Audio Program Guide: CCU 5 | 2007: CCU 5 | 2007 Audio
 
  Go to interview with Herbert I Hurwitz, MD
Go to interview with Joel E Tepper, MD
Go to interview with Richard M Goldberg, MD
Go to interview with Cathy Eng, MD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
Herbert I Hurwitz, MD Herbert I Hurwitz, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Clinical Director, Phase I Program
Co-leader, GI Oncology Program
Duke University Medical Center
Durham, North Carolina
  
  Click here to download the entire interview  
Track 1 Clinical decision-making in the use of adjuvant therapy for patients with Stage II colorectal cancer (CRC)
Track 2 Counseling patients about the risks and benefits of adjuvant therapy
Track 3 Adjuvant capecitabine monotherapy for patients with lower-risk disease
Track 4 Monitoring patients for oxaliplatin-associated neuropathy
Track 5 Dosing capecitabine monotherapy in the adjuvant setting
Track 6 Patient follow-up after adjuvant therapy
Track 7 Management of potentially curable metastatic CRC (mCRC)
Track 8 Treatment algorithm for patients with resectable versus unresectable mCRC
Track 9 Utilization of response to preoperative therapy as an in vivo test of chemosensitivity
Track 10 Therapeutic approach to unresectable mCRC and an asymptomatic, synchronous primary tumor
Track 11 Avoiding surgical intervention for patients with intact, asymptomatic primary tumors
Track 12 Selection of appropriate patients for first-line therapy with a fluoropyrimidine/ bevacizumab treatment platform
audio
Track 13 Addition of bevacizumab to FOLFOX versus FOLFIRI for the treatment of mCRC
audio
Track 14 Treatment holidays in the management of mCRC
audio
Track 15 Dosing of bevacizumab
audio
Track 16 Continuation of bevacizumab after disease progression: The iBET trial
audio
Track 17 Treatment after progression on first-line FOLFOX/bevacizumab
audio
Track 18 Reintroduction of oxaliplatin after discontinuation due to drug-related toxicity
audio
Track 19 Clinical trial endpoints in the evaluation of biologic and targeted agents
audio
     
Joel E Tepper, MD Joel E Tepper, MD
Hector McLean Distinguished Professor of Cancer Research
Department of Radiation Oncology
UNC/Lineberger Comprehensive Cancer Center
UNC School of Medicine
Chapel Hill, North Carolina
  
  Click here to download the entire interview  
Track 1 Current clinical trial objectives in rectal cancer
Track 2 Clinical trials evaluating oxaliplatin as part of neoadjuvant therapy of rectal cancer
Track 3 Incorporating capecitabine as part of neoadjuvant treatment of rectal cancer
Track 4 Combining EGFR inhibition with radiation therapy in rectal cancer
Track 5 Vascular normalization as a rationale for combining bevacizumab with radiation therapy
Track 6 Tumor and nodal staging errors with the use of endoscopic ultrasound
Track 7 Role of MRI in rectal cancer
Track 8 Treatment algorithm for local and systemic therapy of rectal cancer
Track 9 Use of postoperative adjuvant chemotherapy for rectal cancer
Track 10 Adequacy of lymph node sampling in rectal cancer
Track 11 Treatment for patients presenting with synchronous primary rectal tumors and metastatic disease
Audio
Track 12 Abdominoperineal (AP) resection in the community versus specialty centers
Audio
Track 13 Local excision for rectal cancer
Audio
Track 14 New directions in the treatment of anal cancer
Audio
Track 15 Modification of radiation therapy techniques in the treatment of anal cancer
Audio
     
Richard M Goldberg, MD Richard M Goldberg, MD
Professor and Chief
Division of Hematology/Oncology
Associate Director
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
  
  Click here to download the entire interview  
Track 1 Clinical implications of the updated analyses of the MOSAIC adjuvant trial
Track 2 Adjuvant FOLFOX in elderly patients with CRC
Track 3 NCCTG adjuvant trial N0147 of FOLFOX with or without cetuximab
Track 4 Factors contributing to inadequate lymph node sampling in CRC
Track 5 Recent clinical trial results in mCRC
Track 6 FOLFOX/bevacizumab as first-line therapy in mCRC
Track 7 Clinical trial strategies to evaluate novel therapies
Track 8 Evaluating agents as potential radiation sensitizers in rectal cancer, including capecitabine, oxaliplatin and bevacizumab
Track 9 ACOSOG trial of laparoscopic versus conventional resection of rectal cancer

     
Cathy Eng, MD Cathy Eng, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Adjuvant capecitabine for patients with lower-risk disease
Track 2 Disease-free survival as a surrogate endpoint for overall survival
Track 3 NCCTG-N0147: Adjuvant FOLFOX with or without cetuximab
Track 4 New research issues in anal cancer
Track 5 Clinical trial of CAPOX with radiation therapy for anal cancer
Track 6 RTOG-9811: Use of mitomycin C versus cisplatin chemotherapy for anal cancer
Track 7 Clinical trial of cisplatin, fluorouracil, cetuximab and radiation therapy for HIV-associated anal cancer
arrow
Track 8 Clinical trial of 5-FU/bevacizumab in combination with radiation therapy for rectal cancer
arrow
Track 9 Neoadjuvant capecitabine and oxaliplatin for rectal cancer
arrow
Track 10 Prognostic value of the ratio of sampled-to-positive lymph nodes
arrow